Arbutus Biopharma (ABUS) 10-Q2023 Q1 Quarterly report

Filed: 4 May 23, 4:07pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: advice, begun, blockade, booster, capacity, checkpoint, clarity, composition, counsel, credit, denial, Department, exhibit, Fifty, flare, Food, fulfill, goal, high, immunotherapeutic, individually, induction, Jersey, judicial, Justice, largely, legal, letter, lifted, lifting, maintenance, Mechanistically, monoclonal, mutually, nivolumab, notified, official, Opdivo, ordinary, pharmacokinetic, potency, Prepaid, Pretrial, protocol, recover, recovery, regulating, remove, stability, strive, Summit, thirty, timepoint, twenty, typically, unable, unvested, verbal, vest, withdrew

Removed: adding, additive, adequately, AEs, alleging, alternative, animal, annually, annum, ASPIN, assumption, asymptomatic, attributable, bifurcation, block, British, cccDNA, cell, chain, clinically, cohort, collected, Columbia, commence, commenced, community, compensate, compliance, compounded, compounding, computing, conduct, consisting, consolidation, converted, coupon, currency, cycle, deficit, delayed, demonstrate, digit, disoproxil, disrupt, disrupted, disruption, double, driven, economy, emergent, enabling, enrolled, ensuing, evacuation, expired, feature, fixed, foreign, formation, fumarate, GAAP, generate, governmental, growth, hospital, impaired, implemented, inability, incur, initially, instituted, intact, interrupted, invalidity, invasion, investigate, jeopardize, leaving, led, lockup, lost, magnitude, mandate, mandatory, meaningful, military, mission, monitoring, movement, National, netted, noted, Nucleotide, PA, pandemic, pangenotypic, participate, persist, persistence, petition, planned, plateau, predetermined, prioritization, ratio, reallocation, redemption, relevant, reservoir, restrict, ruling, Russia, selectively, serum, settled, significantly, site, spread, standstill, state, statistically, step, subscription, suspended, tenofovir, tolerated, triple, UBC, Ukraine, uncoating, undeniable, undertaken, University, upholding, valid, violence, Viread, vital, volatility, war, warfare, Warminster, wholly, work, world

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ABUS transcripts

ABUS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation (the “Company”) for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I William Collier, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.

Date: May 4, 2023


			/s/ William Collier
			Name: William Collier
			Title: President and Chief Executive Officer